問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital Yunlin Branch  (在職)

Division of General Internal Medicine

Digestive System Department

National Taiwan University Hospital Yunlin Branch (在職)

Digestive System Department

國立臺灣大學醫學院附設醫院雲林分院

Division of General Internal Medicine

更新時間:2023-09-19

陳健弘Chen, Chien-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

篩選

List

57Cases

2025-04-01 - 2030-06-18

Phase III

Active
A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Injectables Injectables Injectables

Participate Sites
8Sites

Recruiting8Sites

2023-09-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-11-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2019-07-01 - 2026-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2017-11-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated9Sites

陳三奇
Taipei Veterans General Hospital

Division of Hematology & Oncology

2023-01-30 - 2028-11-27

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2018-11-30 - 2025-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting8Sites

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

2022-03-31 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting1Sites

2021-07-01 - 2024-07-26

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2024-01-01 - 2030-11-30

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites